These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study.
    Author: van Beek EJ, von der Möhlen MA, ten Cate JW, Brandjes DP, Büller HR.
    Journal: Neth J Med; 1994 Nov; 45(5):206-10. PubMed ID: 7830846.
    Abstract:
    OBJECTIVE: To assess the clinical utility of antithrombin III (AT-III) substitution in adults with septicaemia in an intensive care unit. METHODS: A retrospective follow-up study was performed in the adult intensive care unit of a large teaching hospital. Adults with septicaemia and AT-III levels less than 0.45 IU/ml were identified. AT-III administration, consisting of an intravenous bolus injection of 20 IU/kg, followed by continuous infusion of 20 IU/kg per 24 h, was given to 21 patients, while this was withheld in 21 age- and sex-matched controls. The severity of diffuse intravascular coagulation (DIC), APACHE II score, and type of septicaemia were analysed. The odds ratio was calculated for survival. RESULTS: The base-line characteristics with regards to severity of DIC, APACHE scores and types of sepsis were comparable for the patients who received AT-III concentrates and those who did not. Mortality in the treated and non-treated groups was 76% (95% CI: 53-92%) and 57% (95% CI: 34-78%), respectively (p = 0.24). The odds ratio for survival was 2.4 if no AT-III concentrate was administered (95% CI: 0.537-11.5; p = 0.24). CONCLUSIONS: The use of AT-III concentrates in the doses applied in adult intensive care patients with septicaemia does not appear to improve outcome in terms of mortality.
    [Abstract] [Full Text] [Related] [New Search]